They more recently demonstrated that high serum levels of IL-9 in DLBCL patients correlate with prolonged survival and reduced sensitivity to chemotherapeutic drugs of neoplastic cells [77]. The gene discussed is IL9; the disease is diffuse large B-cell lymphoma.